Antimicrobial susceptibility patterns of respiratory Gram-negative bacterial isolates from COVID-19 patients in Switzerland

3 Marina Gysin^{1*}, Claudio Tirso Acevedo^{2*}, Klara Haldimann^{1*}, Elias Bodendoerfer¹, Frank

Imkamp¹, Karl Bulut¹, Philipp Karl Buehler³, Silvio Daniel Brugger², Katja Becker¹, Sven N.
 Hobbie^{1**}

- 6 ¹ Institute of Medical Microbiology, University of Zurich, Gloriastrasse 30, 8006 Zurich, Switzerland
- ² Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich,
 Raemistrasse 100, 8091 Zurich, Switzerland
- ³ Institute for Intensive Care Medicine, University Hospital Zurich and University of Zurich, Raemistrasse 100,
 8091 Zurich, Switzerland
- 11 *MG, CTA, and KH contributed equally to this study; **correspondence: sven.hobbie@uzh.ch

12 **Corresponding author:**

- 13 Dr. Sven Hobbie
- 14 University of Zurich
- 15 Institute of Medical Microbiology
- 16 Gloriastrasse 30
- 17 CH-8006 Zurich
- 18 Phone +41 44 634 22 84
- 19 E-mail: sven.hobbie@uzh.ch
- 20

21

- 22 23
- 25
- 24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 ABSTRACT

26 Background

- 27 Bacterial superinfections associated with COVID-19 are common in ventilated ICU patients and impact
- 28 morbidity and lethality. However, the contribution of antimicrobial resistance to the manifestation of
- 29 bacterial infections in these patients has yet to be elucidated.

30 Methods

We collected 70 Gram-negative bacterial strains, isolated from the lower respiratory tract of ventilated COVID-19 patients in Zurich, Switzerland between March and May 2020. Species identification was performed using MALDI-TOF; antibiotic susceptibility profiles were determined by EUCAST disk diffusion and CLSI broth microdilution assays. Selected *Pseudomonas aeruginosa* isolates were analyzed by whole-genome sequencing.

36 Results

37 P. aeruginosa (46%) and Enterobacterales (36%) comprised the two largest etiologic groups. Drug 38 resistance in P. aeruginosa isolates was high for piperacillin/tazobactam (65.6%), cefepime (56.3%), 39 ceftazidime (46.9%) and meropenem (50.0%). Enterobacterales isolates showed slightly lower levels 40 of resistance to piperacillin/tazobactam (32%), ceftriaxone (32%), and ceftazidime (36%). All 41 P. aeruginosa isolates and 92% of Enterobacterales isolates were susceptible to aminoglycosides, with 42 apramycin found to provide best-in-class coverage. Genotypic analysis of consecutive P. aeruginosa 43 isolates in one patient revealed a frameshift mutation in the transcriptional regulator nalC that 44 coincided with a phenotypic shift in susceptibility to β -lactams and quinolones.

45 Conclusions

46 Considerable levels of antimicrobial resistance may have contributed to the manifestation of bacterial 47 superinfections in ventilated COVID-19 patients, and may in some cases mandate consecutive 48 adaptation of antibiotic therapy. High susceptibility to amikacin and apramycin suggests that 49 aminoglycosides may remain an effective second-line treatment of ventilator-associated bacterial 50 pneumonia, provided efficacious drug exposure in lungs can be achieved.

- 51
- 52
- 53
- 54

55 KEYWORDS

56 COVID-19, superinfection, ventilator-associated bacterial pneumonia, antimicrobial resistance,
 57 aminoglycoside, apramycin

59 BACKGROUND

- 60 The emergence of the coronavirus disease 2019 (COVID-19) has resulted in high rates of intensive care
- 61 unit (ICU) admissions of critically ill patients [1] suffering from acute respiratory distress syndrome
- 62 (ARDS) [2,3]. Respiratory viral infections predispose patients to secondary bacterial infections which
- are associated with increased morbidity and case fatality rates [4,5]. Particularly, secondary bacterial
- 64 infections acquired in the setting of ICU-treatment are also independently associated with higher risk
- of mortality when compared with community-acquired infections [6].
- 66 Secondary bacterial infections in COVID-19 patients, hereafter referred to as superinfections, have not been intensively investigated thus far. Yet, mainly small cohort studies have reported high 67 superinfection rates in critically ill and/or deceased COVID-19 patients. For instance, a retrospective 68 69 cohort study by Zhou et al. documented secondary infections in 50% of deceased COVID-19 patients 70 and ventilator-associated pneumonia (VAP) in a third of mechanically ventilated patients, despite the 71 fact that 95% of patients received antibiotic treatment [7]. A study by Du et al. described secondary 72 bacterial infections at a late stage of disease in 10 of 21 deceased patients with the etiological 73 spectrum including Klebsiella pneumoniae, Staphylococcus spp., Acinetobacter baumannii and 74 Escherichia coli [8]. However, a comprehensive antimicrobial resistance (AMR) surveillance of
- 75 bacterial superinfection in critically ill COVID-19 patients treated in the ICU has yet to be reported.
- In recent years, the incidence of infections caused by gram-negative bacilli (GNB), especially 76 77 multidrug-resistant (MDR) organisms, in highly susceptible ICU patients has increased [9,10]. 78 Particularly infections caused by MDR GNB are associated with a substantial risk of morbidity and in-79 hospital mortality for the critically ill [6]. The increased exposure of patients to antimicrobials and the 80 global surge in hospital and especially ICU admissions due to the COVID-19 pandemic are rising concerns on the long-term impact on AMR in the acute care setting [11–13]. During the beginning of 81 82 the COVID-19 pandemic, uncertainty regarding the novel disease has resulted in high antibiotic use since empirical antibiotic treatment was commonly prescribed before or at the time of hospital 83 84 admission. A meta-analysis by Rawson et al. revealed that 72% of hospitalized patients received 85 antimicrobial therapy despite low initial evidence of community-acquired co-infections at that time [14]. Similarly, the ISARIC WHO Clinical Characterization Protocol reported preceding anti-infective 86 87 treatment in 76.6% of hospitalized patients [15].
- A detailed understanding of the epidemiology and AMR pattern of bacterial superinfections in critically ill COVID-19 patients is urgently needed for adequate treatment. Here we report the bacterial spectrum and the antimicrobial susceptibility patterns of respiratory GNB isolated from ventilated ICU patients during the first COVID-19 wave in Switzerland. In addition, we investigate changes in the antimicrobial resistance over time for a single *P. aeruginosa* infection under antibiotic therapy using whole-genome sequencing (WGS).

95 METHODS

96 Study population

97 This study was conducted within the MicrobiotaCOVID cohort, a single-center, prospective 98 observational study conducted at the University Hospital Zurich, Switzerland. The study was approved 99 by the Local Ethics Committee of the Canton of Zurich, Switzerland (Kantonale Ethikkommission Zurich 100 BASEC ID 2020 – 00646). All patients with confirmed SARS-CoV-2 infection admitted to the ICU 101 requiring mechanical ventilation between March and May 2020 were included (*n* = 40). SARS-CoV-2 102 was detected by real-time RT-PCR as previously described [16]. Informed consent of all patients was

103 obtained. The study cohort during this time period has been described recently [17].

104 Sample collection

- 105 Longitudinal sample collection, processing and testing was performed as described recently [17]. In
- 106 brief, the following sampling was performed: If the clinical situation allowed, bronchoalveolar lavages
- 107 (BAL) with 10ml of saline were collected by the ICU personnel upon ICU admission and during the later
- 108 course of the disease if clinically indicated. Tracheobronchial secretions (TBS) were collected from
- each intubated patient at least on day 0 (i.e., upon ICU admission), day 1, day 2, day 3, day 5 and
- 110 henceforth every 5 days. If the clinical situation as determined by the ICU attending physician did not
- allow TBS collection, no sampling was performed. Samples were initially processed at the diagnostic
- 112 laboratory of the Institute of Medical Microbiology (IMM) in the course of routine diagnostics. Species
- identification was performed with MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) using the
- direct formic acid transfer method [18]. Repetitive detected isolates of the same species in the same
- patients were included to monitor changes in antimicrobial susceptibility over time.

116 Antimicrobial susceptibility testing (AST)

Bacterial isolates were inoculated onto Columbia sheep blood (COS) agar and were incubated for 24 117 hours prior to antimicrobial susceptibility testing. The European Committee on Antimicrobial 118 119 Susceptibility Testing (EUCAST) disk diffusion method (version 8.0, January 2020) [19] was applied to 120 determine the isolate's antimicrobial susceptibility to piperacillin/tazobactam (TPZ36), 121 amoxicillin/clavulanate (AMC30), ceftriaxone (CRO30), cefepime (FEP30), meropenem (MEM10), 122 amikacin (AK30), tobramycin (TOB10), gentamicin (CN10), trimethoprim/sulfamethoxazole (SXT25) 123 ceftazidime (CAZ10) and ciprofloxacin (CIP5). The antibiotic SirScan Disks were obtained from i2a 124 Diagnostics, Montpellier, France. Interpretative criteria in the EUCAST guidelines 2020 [20] were applied to set clinical resistance breakpoints and translate inhibition zone diameters into either 125 resistant (R) or non-resistant (susceptible, S and "susceptible, increased exposure" (intermediate), I) 126 127 phenotypes. Interpretative criteria for *P. aeruginosa* resistance to GEN were derived from the EUCAST guidelines 2019 [21] instead, since they have been removed from the 2020 version. Interpretative 128 criteria for Burkholderia cenocepacia resistance to MEM and SXT (Table S4) were derived from the 129 130 Clinical and Laboratory Standards Institute (CLSI) guidelines 2020 [22].

Antimicrobial susceptibilities were further assessed by broth microdilution assays following the CLSI guidelines [22,23]. Interpretative criteria in the EUCAST guidelines 2020 were followed to set clinical breakpoints and translate MICs into drug susceptibility. Interpretative criteria for *P. aeruginosa* resistance to GEN were derived from the EUCAST guidelines 2019 instead, since they have been

- removed from the 2020 version. For the aminoglycoside plazomicin, the FDA-identified interpretative
- 136 criteria of 2, 4, and ≥ 8 mg/L were used for susceptible, intermediate, and resistant, respectively [24].
- 137 The minimal inhibitory concentration (MIC) performance standard for the aminoglycoside apramycin
- 138 was set to a modal value of 4 mg/L for *E. coli* ATCC 25922 and an acceptable range of 2-8 mg/L.
- 139 Epidemiological cut-off values (ECOFFs) of 8 mg/L for *Enterobacterales* and 16 mg/L for *P. aeruginosa*
- 140 were used as interpretative criteria [25].

141 Whole-Genome Sequencing of selected *P. aeruginosa* isolates

- Whole-genome sequencing was applied to detect resistance determinants of eight selectedconsecutive *P. aeruginosa* isolates from a single patient.
- 144 DNA was extracted from cultures of the clinical isolates grown on Columbia sheep blood (COS) agar 145 plates using the DNeasy® UltraClean® Microbial kit (Qiagen, Hilden, Germany) according to the 146 manufacturer's recommendations. Library preparation was performed using the Qiagen® QIAseq FX 147 DNA kit (Qiagen, Hilden, Germany), according to manufacturer's instructions. Sequencing library 148 quality and size distribution were analyzed on a fragment analyzer automated CE system (Advanced 149 Analytical Technologies Inc., Heidelberg, Germany), using the fragment analyzer 474 HS next 150 generation sequencing (NGS) kit. Sequencing libraries were pooled in equimolar concentrations and 151 paired-end sequenced (2 × 150 bp) on an Illumina MiSeq platform (Illumina[®], San Diego, CA, USA).
- Raw sequencing reads (FASTQ) were filtered and trimmed using Trimmomatic [26]. CONTIGS were assembled from processed FASTQ files using SPAdes (v3.13.0). To identify antibiotic resistance determinants CONTIGS were analyzed using the command line version of Resistance Gene Identifier
- 155 (RGI; v4.2.2) and CARD (Comprehensive Antibiotic Resistance Database, v3.1.0) [27,28].

156

158 **RESULTS**

159 Species distribution

Out of a total of 314 respiratory samples (289 TBS and 25 BAL) 168 GNB isolates were detected, in 19 of the 40 patients (48%). A representative subset of 70 GNB, including repetitive isolates from 17 patients, were further analyzed in this study. More information about the 17 patients is provided in the Supplementary Information (Table S1).

164 The two largest groups of pathogens in our panel of COVID-19 GNB isolates were Pseudomonas aeruginosa (46%) and Enterobacterales (36%). Burkholderia cenocepacia (17%) was found in smaller 165 166 numbers, as well as a single Acinetobacter bereziniae isolate (Figure 1A). Within the order of Enterobacterales, Enterobacter cloacae (32%) and Klebsiella pneumoniae (28%) were the two 167 predominant species, followed by Klebsiella aerogenes (20%), Citrobacter spp. (16%), and 168 Escherichia coli (4%) (Figure 1B). The species distribution of the analyzed subset (n = 70) was shown 169 170 to be representative for all the identified Gram-negative isolates of the MicrobiotaCOVID cohort 171 (*n* = 168, Figure S1).

172



Figure 1. Subset distribution of all Gram-negative respiratory isolates studied (a) and further differentiation within the order of *Enterobacterales* (b).

- 173
- 174
- 175

176 Antimicrobial susceptibility patterns

177 The antimicrobial susceptibility profile of all *Enterobacterales* and *P. aeruginosa* isolates (*n* = 57) was 178 determined by the EUCAST disk diffusion method (Figure 2, Table S2).

A high proportion of *P. aeruginosa* isolates was found to be resistant to the standard-of-care antibiotics cefepime (FEP, 56.3%), ceftazidime (CAZ, 46.9%), and meropenem (MEM, 50.0%). *P. aeruginosa* resistance to piperacillin/tazobactam (TZP, 65.6%) was the highest for any of the relevant drugs tested in this study. Resistance to ciprofloxacin (CIP) was comparatively low in *P. aeruginosa* isolates (15.6%).

184 Enterobacterales isolates showed likewise resistance to TZP (32.0%), ceftriaxone (CRO, 32.0%), and 185 (36.0%). The Enterobacterales resistance FEP CAZ was lower for (8.0%) and trimethoprim/sulfamethoxazole (SXT, 4.0%). 186

Disk diffusion further revealed all the *P. aeruginosa* isolates to be susceptible to gentamicin (GEN), tobramycin (TOB), and amikacin (AMI). Aminoglycoside susceptibility was also high for the *Enterobacterales* isolates with only a single *E. coli* isolate lacking susceptibility to gentamicin and tobramycin.

To study the antimicrobial susceptibility profiles in more detail and to test additional antibiotics not routinely included in the disk diffusion panel, the clinical isolates were also analyzed by broth microdilution assays to determine the minimal inhibitory concentration (MIC) (Figure 3, Table S3). For those drugs tested by both disk diffusion and broth microdilution, the results correlated well between the two methodologies (Figure S2 and S3).

Broth microdilution assays confirmed the results of the disk diffusion assay with regards to high aminoglycoside susceptibility of both *P. aeruginosa* and *Enterobacterales* and extended the aminoglycoside panel by including plazomicin (PLZ) and apramycin (APR). Both PLZ and APR showed full coverage of *Enterobacterales*. Apramycin additionally showed full coverage of *P. aeruginosa* (Figure 3, Table S3).



Figure 2. Inhibition zone diameter distributions for respiratory *Enterobacterales* and *P. aeruginosa* isolates from ventilated COVID-19 patients. Vertical dashed lines indicate the EUCAST clinical resistant breakpoint values for piperacillin/tazobactam (TZP), cefepime (FEP), ceftazidime (CAZ), meropenem (MEM), ciprofloxacin (CIP), gentamicin (GEN), tobramycin (TOB), amikacin (AMI), amoxicillin/clavulanate (AMC), ceftriaxone (CRO) and trimethoprim/sulfamethoxazole (SXT) for *Enterobacterales* (orange) and *P. aeruginosa* (blue) isolates, respectively.



Figure 3. Minimal inhibitory concentration (MIC) distributions for respiratory *Enterobacterales* and *P. aeruginosa* isolates from ventilated COVID-19 patients. Vertical dashed lines indicate the EUCAST clinical resistant breakpoint values for piperacillin/tazobactam (TZP), cefepime (FEP), meropenem (MEM), gentamicin (GEN), tobramycin (TOB), amikacin (AMI) and trimethoprim/sulfamethoxazole (SXT) for *Enterobacterales* (orange) and *P. aeruginosa* (blue) isolates, respectively. In the case of plazomicin (PLZ), the vertical dashed line indicates the FDA-identified interpretative criteria. In the case of APR (apramycin), vertical dashed lines indicate the proposed ECOFF values [25].

203

205 Antibiotic resistance development in *P. aeruginosa* under antimicrobial selection pressure

Next, we analyzed bacterial isolates that were repetitively derived from individual patients to study
changes to antimicrobial susceptibility in response to antibiotic therapy. A decrease in antimicrobial
susceptibility over the course of treatment was particularly pronounced for *P. aeruginosa* (Figure S4).
This prompted us to select a single *P. aeruginosa* infection for the analysis of phenotypic and genotypic
changes in response to antibiotic therapy across eight consecutive isolates collected on day 9, 10, 16,
17, 18, 22, 29 and 37 (Figure 4).

The patient was initially admitted to the ICU of a regional hospital due to severe COVID-19 pneumonia. 212 213 He had to be intubated and mechanically ventilated because of respiratory failure. After 2 days the 214 patient was referred to the ICU of the University Hospital Zurich, a tertiary care hospital, because of 215 pulmonary deterioration and worsening of inflammatory parameters and empiric antibiotic therapy 216 for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) was started with 217 piperacillin/tazobactam. At this point, the patient had developed severe ARDS (oxygenation index 85 218 mmHg). Initial isolation of *Pseudomonas aeruginosa* from TBS occurred shortly after on day 4 after 219 ICU admission (Figure S4, ID 05). After seven days of antibiotic therapy with piperacillin/tazobactam (TZP) resistance was not only detected against this broad-spectrum β -lactam antibiotic/ β -lactamase 220 221 inhibitor combination, but also against third and fourth generation cephalosporins (CAZ and FEP) (Figure 4). Consecutively, antibiotic therapy was switched to meropenem (MEM) and subsequent 222 223 isolates (isolates 2 and 3) yet again showed susceptibility to TZP and cephalosporins (CAZ and FEP). After eight days of antibiotic therapy with MEM, repetitive isolates showed resistance to MEM 224 225 (isolates 4 to 8) and eventually to TZP as well as extended-spectrum cephalosporins (CAZ and FEP), 226 indicating a multidrug-resistant gram-negative (MDRGN) infection. In the meantime, the patient 227 showed clinical improvement and had been successfully weaned from the respirator. Despite elevated 228 inflammatory parameters the antimicrobial treatment was stopped for an antibiotics-free period. 2 229 days after stopping the antibiotic therapy, purulent endotracheal aspiration was obtained and therapy 230 with ciprofloxacin (CIP) was initiated and continued for 9 days. Gentamicin was added because of 231 pulmonary deterioration (Figure 4 and Figure S4, ID 05). Due to ongoing deterioration and after resistance to fluoroquinolones including CIP occurred, antibiotic therapy was switched to 232 233 ceftazidime/avibactam (CZA) for a total of 11 days. Under antibiotic therapy with CZA the patient 234 showed again clinical improvement but *P. aeruginosa* was still detectable throughout antibiotic 235 treatment. Eventually the patient was successfully extubated on day 40 after initial ICU admission and intubation. Therapy with inhaled tobramycin (TOB) was started 2 days before extubation but was 236 237 stopped again after a total of 6 days, as P. aeruginosa was still detectable and the patient showed no 238 signs of acute infection, thus indicating ongoing colonization of the patient with MDR P. aeruginosa.

239 Finally, we performed whole-genome sequencing of the eight consecutive isolates in an attempt to 240 detect possible resistance determinants that may explain the phenotypic progression (Excel file S1). 241 Whole-genome analysis indicated that all eight isolates originated from the same clone indeed. The 242 clone was characterized by two β -lactamases that commonly occur in *P. aeruginosa*: an OXA-50 like 243 type and PDC-91. A 1-bp deletion causing a frameshift in the gene encoding the transcriptional 244 regulator NaIC of the mexAB-oprM multidrug efflux pump operon was found in isolates 4 till 8, but 245 was absent in the first three isolates, providing a rationale for the drop in susceptibility from day 17 246 onwards (Figure 4).



Figure 4. Antibiotic resistance development of *P. aeruginosa* in a single patient during antibiotic therapy. (a) The disc diffusion inhibition zones for piperacillin/tazobactam (TZP), meropenem (MEM), ciprofloxacin (CIP), ceftazidime (CAZ), cefepime (FEP), tobramycin (TOB) and gentamicin (GEN) are shown for eight consecutive isolates (labeled from 1-8), collected after 9, 10, 16, 17, 18, 22, 29 and 37 days of ICU admission. Horizontal dashed lines indicate the EUCAST clinical resistant breakpoint values for TZP (18mm), MEM (18mm), CIP (26mm), CAZ (17mm), FEP (21mm), TOB (18mm) and GEN (15mm), respectively. The bracket describes the resistance determinant detected in the *P. aeruginosa* isolates by whole-genome sequencing. (b) Antibiotic therapy of the patient. Piperacillin/tazobactam (TZP), meropenem (MEM), ciprofloxacin (CIP), gentamicin (GEN), ceftazidime/avibactam (CZA) and tobramycin (TOB).

247

249 DISCUSSION

This study belongs to a group of early microbiological studies that report a detailed antimicrobial susceptibility profiling of Gram-negative bacterial superinfections in ventilated COVID-19 patients. The sample size is limited and has a strong geographic bias, but some important conclusions can nevertheless be drawn and will add to a growing number of similar studies that we expect from other geographic locations.

The etiology found here for late-onset VAP in COVID-19 patients resembles the diversity of Gramnegative pathogens typically found in nosocomial pneumonia [29]. Previous cohort studies have reported diverse etiology in COVID-19 confirmed cohorts, with *A. baumannii*, *K. pneumoniae*, *E. coli* and *P. aeruginosa* as predominant infecting agents [30–32].

Besides *P. aeruginosa* and *Enterobacterales, Burkholderia cenocepacia* were the third most common isolates encountered in this study. The latter is regarded a natural colonizer and an opportunistic pathogen in immune-compromised patients, with a naturally high intrinsic resistance to various antibiotics [33]. Trimethoprim-sulfamethoxazole (SXT) is used as a first-line option for the suppression/control of the infection. Since we only had a small number of *B. cenocepacia* isolates in our study, all of which were susceptible to SXT (Table S4), we decided to focus further analysis on only *P. aeruginosa* and *Enterobacterales*.

P. aeruginosa represents a notorious pathogen of nosocomial infections often characterized by MDR,
 especially in VAP and cystic fibrosis patients [34,35]. Treatment success is greatly hampered due to its
 intrinsic and adaptive resistance to nearly all available antipseudomonal agents. Important
 determinants driving resistance in *P. aeruginosa* are multidrug efflux pumps, alterations to its outer
 membrane porins, and the expression of β-lactamases [36]. For the *P. aeruginosa* isolates analyzed
 here, we found very high levels of drug resistance to TZP, FEP, CAZ and MEM.

272 For the Enterobacterales isolates we found a relatively high level of resistance to TZP, CRO, CAZ, and 273 AMC. This may be explained by prior selection related to early antibiotic treatment in the course of 274 COVID-19 infection, since AMC, CRO, and TZP are commonly used in Switzerland as first-line drugs for 275 nosocomial bacterial pneumonia. Some of the species within the order of Enterobacterales are further 276 characterized by a chromosomally encoded AmpC β -lactamase, which also contributes to decreased 277 susceptibility to selected β -lactam antibiotics and in particular AMC [37]. The high resistance of 278 Enterobacterales to amoxicillin/clavulanate (AMC, 72.0%) was not surprising considering intrinsic 279 (chromosomal) AmpC genes of E. cloacae, K. aerogenes, and C. freundii [37]. Enterobacterales 280 resistance to FEP, SXT, MEM and aminoglycosides was low or absent in comparison to the aforementioned antibiotics. Only a single E. coli isolate (Figure 2 and 3 and Figure S2), showed 281 282 resistance to gentamicin and tobramycin, without prior exposure to aminoglycosides in the patient's 283 treatment regimen.

Our findings seem to be generally aligned with those of several other reports from countries that experienced a high incidence of severe COVID-19 cases, which proposed an increase in MDR bacterial infections in severely ill COVID-19 patients [32,38–41]. However, it is conceivable to assume that the species distribution and specific resistance patterns within individual studies may vary depending on the geographic and local ICU etiology of resistant isolates, study-specific patient recruitment and sample selection, and the treatment history of prior antibiotic exposure in regular VAP patients andCOVID-19 patients.

There is no evidence to assume that the antimicrobial resistance rates in ventilated COVID-19 patients differ significantly from resistance rates from non-COVID-19 ventilated ICU patients and underlie mainly local ICU epidemiology. Surveillance of MDR infections in ventilated ICU patients during and after the COVID-19 pandemic is required to adequately monitor a putative increased incidence of MDR infections in this specific patient population.

In the present study, antibiotic resistance levels seemed to increase over the course of antibiotic 296 297 treatment in the P. aeruginosa isolates (Figure 4 and Figure S4). Resistance to TZP but also to third-298 and fourth-generation cephalosporins (CAZ and FEP, respectively) occurred on day 7 of TZP therapy 299 as reflected in isolate 1 (Figure 4). This may be attributable to the two β -lactamases (OXA-50 like type 300 and PDC-91) which were identified by WGS in all eight isolates from that single infection. The OXA-50 301 like type enzyme is a class D β -lactamase, which has a reported narrow hydrolyzing spectrum including 302 piperacillin but not meropenem [42]. PDC-91 is an inducible AmpC-like β -lactamase conferring 303 resistance to broad-spectrum cephalosporins [43]. Surprisingly, we observed a completely susceptible phenotype in isolates 2 and 3. We hypothesize that these two isolates were colonizing a different 304 305 niche in the airway tract, potentially with the formation of a biofilm, which could have limited antibiotic exposure and resulted in a sensitive phenotype in the disc diffusion assay. 306

307 The MexAB-OprM efflux pump is a clinically relevant efflux system in *P. aeruginosa* [37,44]. 308 Transcription of the corresponding genes is under regulation of MexR, NalC and NalD. Overexpression 309 of this efflux pump can be induced by mutations in *nalC*, leading to resistance against β -lactams 310 (except imipenem) and quinolones but not aminoglycosides [45].

311 WGS analysis identified a 1-bp deletion in the suppressor gene nalC of isolates 4 – 8, which likely 312 renders the corresponding protein non-functional and eventually results in over-expression of MexAB-313 OprM. Notably, at the same time we observed a gradual to massive decrease in TZP, CAZ, FEP, CIP and 314 MEM susceptibility in the consecutive isolates (Figure 4), indicating the importance of the nalC mutation in developing the MDR phenotype of isolate 8. However, imipenem has been described as 315 316 unaffected by the MexAB-OprM efflux pump [45]. Hence, the observed resistance to imipenem 317 (Figure S4, ID 05) may be caused by a different resistance mechanism. In addition, expression levels 318 of mexAB-oprM or of oxa-485 and pdc-91 have not been tested, therefore the precise correlation of 319 each drug susceptibility to its resistance mechanism remains to be investigated. Nevertheless, the 320 detected resistance determinants in combination with the antibiotic treatment history provide a rational explanation for the emergence of this MDR P. aeruginosa strain. 321

322 In the case of pneumonia, a main determinant of antibiotic efficacy is the drug concentration in the 323 lung parenchyma tissue. Although intravenous aminoglycosides penetrate in lung parenchyma and 324 bronchial secretions, measured lung tissue concentrations have been found to be relatively low for 325 some aminoglycosides, because plasma concentrations are kept low in clinical care to avoid systemic 326 toxicity [46]. While therapy with inhaled aminoglycosides are well described and tolerated in the 327 treatment of cystic fibrosis, administration of nebulized aminoglycosides in acute pulmonary 328 infections has largely remained an off-label domain and requires further evaluation [47]. Our results warrant further exploration of inhaled aminoglycosides as a critical component in the treatment of 329 HAP/VAP with MDR GNB in COVID-19 patients. The drug candidate apramycin, currently in clinical 330

development, has previously been suggested to have best-in-class coverage of drug-resistant GNB
 [25,48–50], which was confirmed for VAP bacterial isolates from COVID-19 superinfections here.

333

334 CONCLUSION

335 In conclusion, resistance to first-line antibiotics was prevalent in bacterial isolates from ventilated COVID-19 patients in Switzerland during the first wave of COVID-19. It is conceivable that AMR plays 336 337 a key role in those ventilated patients that contract a VAP despite empiric treatment, and contributes 338 to morbidity and case fatality rates of patients that in addition to COVID-19 treatment are likely to 339 receive multi-drug regimens of second-line or last-resort antibiotics to control the bacterial infection. 340 Aminogly cosides have regained interest as potent broad-spectrum antibiotics in the face of β -lactam 341 and specifically carbapenem resistance, and represent a treatment option less toxic than polymyxins. In the present study, Aminoglycosides were the most effective drug class *in-vitro* for the respiratory 342 343 clinical isolates studied here, and the only drug class with full coverage of all *P. aeruginosa* isolates. 344 However, given the relatively low pulmonary tissue penetration and the potential risk of adverse 345 effects at higher dosing, their clinical utility including alternative ways of administration, such as 346 inhalation, will need to be further evaluated in clinical trials for use in patients with resistance to 347 second-line therapies.

348

349 LIST OF ABBREVIATIONS

350	AMI	Amikacin
351	AMC	Amoxicillin/clavulanate
352	APR	Apramycin
353	AST	Antimicrobial Susceptibility Testing
354	CIP	Ciprofloxacin
355	CLSI	Clinical and Laboratory Standards Institute
356	CRO	Ceftriaxone
357	CST	Colistin
358	CAZ	Ceftazidime
359	CZA	Ceftazidime/avibactam
360	ECOFF	Epidemiological Cutoff
361	EUCAST	European Committee on Antimicrobial Susceptibility Testing
362	FEP	Cefepime
363	GEN	Gentamicin
364	GNB	Gram-negative bacilli
365	MEM	Meropenem
366	MIC	Minimal Inhibitory Concentration
367	PLZ	Plazomicin
368	SXT	Trimethoprim/sulfamethoxazole
369	ТОВ	Tobramycin
370	TZP	Piperacillin/tazobactam
371		

372 **DECLARATIONS**

- Ethics approval and consent to participate: The study was approved by the Local Ethics Committee
 of the Canton of Zurich, Switzerland (Kantonale Ethikkommission Zurich BASEC ID 2020 00646). All
 necessary patient/participant consent has been obtained and the appropriate institutional forms have
 been archived.
- 377 Consent for publication: All necessary patient/participant consent has been obtained and the
 378 appropriate institutional forms have been archived.
- 379 **Availability of data and material:** Data generated or analyzed during this study are included in this 380 published article and its supplementary information files. The genome sequencing files generated and 381 analyzed during the current study are available from the corresponding author on reasonable request.
- 382 **Competing interests:** Author SNH is a shareholder in Juvabis AG. All other authors declare no 383 competing interests.
- Funding: This study was partially funded by Innosuisse (project no. 45893.1 INNO-LS). The work was
 supported by the Clinical Research Priority Program of the University of Zurich for the CRPP Precision
 medicine for bacterial infections; and by the University of Zurich, Institute of Medical Microbiology.
- 387 SDB is supported by a Fellowship from the Promedica Foundation (1449/M). The funders had no role
- in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- **Authors' contributions:** All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Marina Gysin, Claudio Tirso Acevedo, Klara Haldimann, Elias Bodendoerfer, Frank Imkamp, Karl Bulut, Katja Becker, and Sven N. Hobbie. The first draft of the manuscript was written by Marina Gysin and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
- Acknowledgements: The authors would like to express their gratitude to Reinhard Zbinden, Annelies
 Zinkernagel and the diagnostic laboratory staff of the Institute of Medical Microbiology for their
 support in accessing the bacterial clinical isolates, in performing MALDI-TOF and disk diffusion
 assays, whole-genome sequencing, and in accessing anonymized clinical information. We would like
- to acknowledge special permit by the University of Zurich to conduct research at the university labs
- 399 during the COVID-19 lockdown period.
- 400
- 401

402 **REFERENCES**

- 403 1. Robertson LC, Al-Haddad M. Recognizing the critically ill patient. Anaesthesia & Intensive Care
 404 Medicine. 2013;14:11–4.
- 405 2. Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: a 406 systematic review and meta-analysis of observational studies. Anaesthesia. 2020;75:1340–9.
- 3. Phua J, Weng L, Ling L, Egi M, Lim C-M, Divatia JV, et al. Intensive care management of coronavirus
 disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020;8:506–17.
- 409 4. Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory Viral Infection-Induced Microbiome 410 Alterations and Secondary Bacterial Pneumonia. Front Immunol. 2018;9:2640.
- 5. Morens DM, Taubenberger JK, Fauci AS. Predominant Role of Bacterial Pneumonia as a Cause of
 Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness. 2009;16.
- 413 6. Vincent J-L, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and 414 Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA. 2020;323:1478–87.
- 7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult
 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395:1054–
 62.
- 8. Du R-H, Liang L-R, Yang C-Q, Wang W, Cao T-Z, Li M, et al. Predictors of mortality for patients with
 COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J.
 2020;55:2000524.
- 421 9. MacVane SH. Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative
 422 Bacterial Infections. J Intensive Care Med. 2017;32:25–37.
- 423 10. Prabaker K, Weinstein RA. Trends in antimicrobial resistance in intensive care units in the United
 424 States. Curr Opin Crit Care. 2011;17:472–9.
- 425 11. WHO | Tackling antimicrobial resistance in the COVID-19 pandemic [Internet]. WHO. World Health
- 426 Organization; [cited 2020 Dec 3]. Available from: http://www.who.int/bulletin/volumes/98/7/20-427 268573/en/
- 428 12. Rawson TM, Ming D, Ahmad R, Moore LSP, Holmes AH. Antimicrobial use, drug-resistant infections
 429 and COVID-19. Nature Reviews Microbiology. Nature Publishing Group; 2020;18:409–10.
- 13. Rawson TM, Moore LSP, Castro-Sanchez E, Charani E, Davies F, Satta G, et al. COVID-19 and the
 potential long-term impact on antimicrobial resistance. Journal of Antimicrobial Chemotherapy.
 2020;75:1681–4.
- 433 14. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and
 434 fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial
 435 prescribing. Clinical Infectious Diseases. 2020;ciaa530.
- 436 15. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK 437 patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective
- 438 observational cohort study. BMJ [Internet]. British Medical Journal Publishing Group; 2020 [cited 2020
- 439 Dec 3];369. Available from: https://www.bmj.com/content/369/bmj.m1985
- 440 16. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel
 441 coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25.
- 442 17. Buehler PK, Zinkernagel AS, Hofmaenner DA, Wendel Garcia PD, Acevedo CT, Gómez-Mejia A, et
- al. Bacterial pulmonary superinfections are associated with longer duration of ventilation in critically
- 444 ill COVID-19 patients. Cell Reports Medicine. 2021;2:100229.

- 18. Haigh J, Degun A, Eydmann M, Millar M, Wilks M. Improved Performance of Bacterium and Yeast
 Identification by a Commercial Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass
 Spectrometry System in the Clinical Microbiology Laboratory. J Clin Microbiol. 2011;49:3441–3441.
- 448 19. EUCAST Disk Diffusion Method for Antimicrobial Susceptibility Testing. Version 8.0 (January 2020).
 449 https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/2020_manu
 450 als/Manual_v_8.0_EUCAST_Disk_Test_2020.pdf.
- 20. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for 451 452 interpretation of MICs diameters. Version 10.0, 2020. and zone 453 https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakp 454 oint_Tables.pdf.
- 455 21. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for 456 interpretation diameters. of MICs and zone Version 9.0, 2019. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpo 457 458 int_Tables.pdf.
- 459 22. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement
 460 M100. Wayne, PA: Clinical Laboratory Standards Institute; 2020.
- 461 23. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically;
- 462 Approved Standard—Ninth Edition. CLSI document M07-A9. Wayne, PA: Clinical and Laboratory
- 463 Standards Institute; 2012.
- 464 24. FDA-Identified Interpretive Criteria for Plazomicin. https://www.fda.gov/drugs/development-465 resources/plazomicin-injection. Accessed 16 December 2020.
- 25. Juhas M, Widlake E, Teo J, Huseby DL, Tyrrell JM, Polikanov YS, et al. *In vitro* activity of apramycin
 against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and *Acinetobacter baumannii*. Journal of Antimicrobial Chemotherapy. 2019;74:944–52.
- 469 26. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. :7.
- 470 27. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, et al. The Comprehensive
 471 Antibiotic Resistance Database. Antimicrob Agents Chemother. 2013;57:3348–57.
- 472 28. Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, et al. CARD 2020:
 473 antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids
 474 Research. 2019;gkz935.
- 475 29. Jones RN. Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator476 Associated Bacterial Pneumonia. CLIN INFECT DIS. 2010;51:S81–7.
- 30. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among
 COVID-2019 cases. Virus Res. 2020;285:198005.
- 31. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et
 al. Incidence of co-infections and superinfections in hospitalised patients with COVID-19: a
 retrospective cohort study. Clinical Microbiology and Infection [Internet]. Elsevier; 2020 [cited 2020
 Aug 7];0. Available from: https://www.clinicalmicrobiologyandinfection.com/article/S1198743X(20)30450-X/abstract
- 484 32. Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiology and antimicrobial resistance of secondary
 485 bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis.
 486 Antimicrob Resist Infect Control. 2020;9:153.
- 487 33. Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resistance Updates.
 488 2016;28:82–90.
- 489 34. Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-
- 490 associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med.
 491 2013;19:216–28.

- 492 35. Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and
 493 Pseudomonas aeruginosa infection. BMC Pulm Med. 2016;16:174.
- 494 36. Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, et al. Epidemiology and
- 495 Treatment of Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa* 496 Infections. Clin Microbiol Reviews. 2019;32:e00031-19, /cmr/32/4/CMR.00031-19.atom.
- 497 37. Li X-Z, Plésiat P, Nikaido H. The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-498 Negative Bacteria. Clin Microbiol Rev. 2015;28:337–418.
- 38. Contou D, Claudinon A, Pajot O, Micaëlo M, Longuet Flandre P, Dubert M, et al. Bacterial and viral
 co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive
 Care. 2020;10:119.
- 39. Nori P, Szymczak W, Puius Y, Sharma A, Cowman K, Gialanella P, et al. Emerging Co-Pathogens:
 New Delhi Metallo-beta-lactamase producing Enterobacterales Infections in New York City COVID-19
 Patients. Int J Antimicrob Agents. 2020;56:106179.
- 40. Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation
 of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect
- 507 Dis. 2020;20:646.
- 41. Porretta AD, Baggiani A, Arzilli G, Casigliani V, Mariotti T, Mariottini F, et al. Increased Risk of
 Acquisition of New Delhi Metallo-Beta-Lactamase-Producing Carbapenem-Resistant Enterobacterales
 (NDM-CRE) among a Cohort of COVID-19 Patients in a Teaching Hospital in Tuscany, Italy. Pathogens.
 2020;9:E635.
- 512 42. Girlich D, Naas T, Nordmann P. Biochemical Characterization of the Naturally Occurring 513 Oxacillinase OXA-50 of Pseudomonas aeruginosa. AAC. 2004;48:2043–8.
- 43. Berrazeg M, Jeannot K, Ntsogo Enguéné VY, Broutin I, Loeffert S, Fournier D, et al. Mutations in β-
- Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal
 Cephalosporins. Antimicrob Agents Chemother. 2015;59:6248–55.
- 44. Pan Y, Xu Y, Wang Z, Fang Y, Shen J. Overexpression of MexAB-OprM efflux pump in carbapenemresistant Pseudomonas aeruginosa. Arch Microbiol. 2016;198:565–71.
- 45. López-Causapé C, Cabot G, del Barrio-Tofiño E, Oliver A. The Versatile Mutational Resistome of
 Pseudomonas aeruginosa. Front Microbiol. 2018;9:685.
- 46. Goldstein I, Wallet F, Robert J, Becquemin M-H, Marquette C-H, Rouby J-J. Lung tissue
 concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am
 J Respir Crit Care Med. 2002;165:171–5.
- 524 47. Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobials via the respiratory tract for
- 525 the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother. 526 2007;60:1216–26.
- 527 48. Becker K, Aranzana-Climent V, Cao S, Nilsson A, Shariatgorji R, Haldimann K, et al. Efficacy of EBL-528 1003 (apramycin) against Acinetobacter baumannii lung infections in mice. Clinical Microbiology and 529 Infection [Internet]. 2020 [cited 2020 14]; Available Dec from: 530 http://www.sciencedirect.com/science/article/pii/S1198743X20307540
- 531 49. Smith KP, Kirby JE. Evaluation of apramycin activity against carbapenem-resistant and -susceptible
- 532 strains of Enterobacteriaceae. Diagn Microbiol Infect Dis. 2016;86:439–41.
- 533 50. Kang AD, Smith KP, Eliopoulos GM, Berg AH, McCoy C, Kirby JE. In vitro Apramycin Activity against
- 534 multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Diagnostic Microbiology
- and Infectious Disease. 2017;88:188–91.
- 536